BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focused on developing novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria, announced that its management will present a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference. The conference is scheduled to take place from September 14-16, 2026, in New York City.
The company’s Chief Financial Officer, Hernan Levett, will deliver a live presentation on September 16, 2026, from 12:30 PM to 1:00 PM ET at the Kennedy II room on the 4th floor of the Lotte New York Palace. In addition, a pre-recorded on-demand presentation by Dr. Marc Gitzinger, Chief Executive Officer, will be available starting September 11, 2026, at 7:00 AM ET, with a replay accessible for 90 days. The webcast can be accessed through the H.C. Wainwright platform or on the BioVersys website in the investor section.
This participation underscores BioVersys’ commitment to advancing its pipeline of antimicrobial candidates. The company leverages two proprietary technology platforms, TRIC and Ansamycin Chemistry, to develop therapies that overcome resistance mechanisms, block virulence production, and directly impact bacterial pathogenesis. This approach aims to address the critical unmet medical need for new treatments against resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders.
BioVersys’ most advanced programs target nosocomial infections caused by Acinetobacter baumannii (BV100, currently in Phase 3) and tuberculosis (alpibectir, in Phase 2, in collaboration with GlaxoSmithKline (GSK) and a consortium led by the University of Lille, France). These efforts are pivotal as the World Health Organization has identified antimicrobial resistance as one of the top global public health threats. The company’s progress in Phase 3 for BV100, which aims to combat hospital-acquired infections, is particularly significant given the rising incidence of MDR Acinetobacter infections.
By presenting at this prestigious conference, BioVersys not only updates investors on its clinical milestones but also highlights its strategic position in the biopharmaceutical sector. The company’s focus on innovative antibacterial solutions is crucial in an era where the development of new antibiotics has been lagging. BioVersys’ approach, combining multiple mechanisms of action, positions it to potentially offer robust solutions against resistant pathogens.
BioVersys is headquartered in Basel, Switzerland, a leading biotech hub. The company’s management team will be available for one-on-one meetings during the conference, providing investors and analysts with deeper insights into its strategy and future plans. The participation in this conference is a key step in enhancing visibility and fostering dialogue with the investment community, as BioVersys continues to advance its pipeline and move closer to delivering new therapeutic options to patients in need.
